Article info

Original research
Attenuating CD3 affinity in a PSMAxCD3 bispecific antibody enables killing of prostate tumor cells with reduced cytokine release

Authors

  1. Correspondence to Dr Pranjali Dalvi; pdalvi{at}teneobio.com
View Full Text

Citation

Dang K, Castello G, Clarke SC, et al
Attenuating CD3 affinity in a PSMAxCD3 bispecific antibody enables killing of prostate tumor cells with reduced cytokine release

Publication history

  • Accepted April 29, 2021
  • First published June 4, 2021.
Online issue publication 
February 24, 2022

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.